SequelSEC

Dolby Laboratories, Inc. DLB

Patent Owners & Lessors · CIK 0001308547 · Fiscal year ends 0927

AnnualQuarterlyTTM
Revenue
$305.00M
Fiscal year ended 2026-06-26
Operating income
$34.32M
Fiscal year ended 2026-06-26
Free cash flow
$152.47M
Fiscal year ended 2026-06-26

Dolby Laboratories, Inc. (DLB) reported revenue of $305.00M and net income of $28.60M for the fiscal year ended 2026-06-26. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Dolby Laboratories, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Patent Owners & Lessors.

Income

Dolby Laboratories, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-262026-03-272025-12-262025-09-262025-06-272025-03-282024-12-272024-09-272024-06-282024-03-29
Revenue$305.00M$395.63M$346.71M$307.02M$315.55M$369.56M$357.00M$304.81M$288.82M$364.52M
Cost of revenue$40.32M$44.73M$43.21M$39.52M$44.00M$35.84M$40.77M$34.00M$35.66M$38.78M
Gross profit$264.68M$350.90M$303.50M$267.50M$271.54M$333.72M$316.22M$270.81M$253.16M$325.75M
Operating income$34.32M$112.95M$62.16M$29.68M$47.64M$107.76M$79.88M$46.35M$36.78M$108.97M
Net income$28.60M$94.92M$53.33M$49.33M$46.07M$91.79M$67.82M$58.57M$38.44M$97.83M
Research & development$65.75M$63.65M$69.08M$67.46M$65.98M$61.71M$66.64M$68.64M$65.50M$62.49M
Weighted-average diluted sharesshares 94.52Mshares 95.52Mshares 96.52MUnavailableshares 96.90Mshares 97.47Mshares 97.15MUnavailableshares 96.96Mshares 96.86M
Pretax income$43.80M$119.70M$71.60M$41.67M$55.52M$120.25M$86.05M$59.73M$50.16M$121.75M
Income tax expense$14.59M$24.24M$17.92M-$8.01M$8.97M$28.02M$17.98M$868.00K$10.51M$23.53M
Diluted EPS$0.30$0.99$0.55Unavailable$0.48$0.94$0.70Unavailable$0.40$1.01
Selling, general & administrative$160.66M$172.12M$161.80M$164.24M$158.47M$160.04M$164.49M$157.11M$146.79M$156.78M
General & administrative$75.58M$75.96M$70.24M$73.72M$72.31M$70.42M$70.09M$69.21M$69.28M$66.74M
Selling & marketing$85.07M$96.16M$91.55M$90.52M$86.16M$89.63M$94.40M$87.90M$77.52M$90.04M

Balance

Dolby Laboratories, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-262026-03-272025-12-262025-09-262025-06-272025-03-282024-12-272024-09-272024-06-282024-03-29
Cash & equivalents$669.39M$594.28M$643.84M$701.89M$698.57M$626.55M$520.82M$482.05M$741.64M$709.54M
Total assets$3.16B$3.25B$3.19B$3.23B$3.20B$3.23B$3.16B$3.11B$2.97B$3.04B
Current assets$1.33B$1.41B$1.41B$1.39B$1.34B$1.39B$1.29B$1.19B$1.47B$1.55B
Total liabilities$563.89M$622.36M$589.25M$595.81M$581.75M$646.02M$641.57M$623.04M$526.20M$607.04M
Current liabilities$416.33M$474.61M$443.51M$437.79M$388.78M$457.48M$441.88M$417.84M$354.54M$442.90M
Total equity incl. NCI$2.59B$2.63B$2.60B$2.63B$2.61B$2.58B$2.52B$2.49B$2.45B$2.44B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$30.77M$31.93M$31.26M$30.42M$32.42M$34.59M$31.83M$33.73M$34.72M$35.80M
Accounts receivable$285.15M$391.29M$373.09M$331.10M$297.61M$314.11M$339.30M$315.46M$285.84M$282.13M
Goodwill$528.34M$529.67M$530.30M$529.90M$528.82M$525.02M$520.42M$533.21M$408.46M$408.65M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$12.47M$20.69M$8.67M$17.84M$17.23M$17.29M$11.55M$17.38M$16.41M$19.73M

Cash flow

Dolby Laboratories, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-262026-03-272025-12-262025-09-262025-06-272025-03-282024-12-272024-09-272024-06-282024-03-29
Operating cash flow$167.46M$92.51M$54.80M$122.83M$67.69M$174.90M$106.78M$116.17M$21.26M$181.41M
Capital expenditures$14.99M$9.06M$4.63M$16.24M$6.43M$6.90M$6.78M$7.38M$7.61M$8.92M
Investing cash flow-$9.79M-$46.09M$1.24M-$21.91M-$6.43M$25.90M-$8.14M-$261.31M-$7.74M-$17.87M
Financing cash flow-$91.02M-$99.88M-$121.83M-$64.06M-$60.74M-$64.87M-$57.57M-$60.12M-$58.40M-$44.16M
Net change in cash$65.08M-$53.76M-$65.80M$36.80M$6.22M$138.68M$33.90M-$200.87M-$45.73M$115.70M
Stock-based compensation$30.96M$30.71M$37.21M$31.05M$30.73M$30.66M$36.07M$29.68M$29.34M$28.92M
Common dividends paid$33.98M$34.34M$34.34M$31.59M$31.63M$31.83M$31.55M$28.61M$28.70M$28.72M
Common share repurchases$65.00M$65.00M$70.00M$35.00M$70.00M$35.00M$15.00M$20.00M$35.00M$25.00M
Depreciation & amortization$22.60M$24.10M$24.14M$22.00M$21.93M$21.54M$22.36M$21.36M$18.31M$18.02M

Derived

Dolby Laboratories, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-262026-03-272025-12-262025-09-262025-06-272025-03-282024-12-272024-09-272024-06-282024-03-29
Free cash flow$152.47M$83.44M$50.17M$106.59M$61.26M$168.00M$100.00M$108.79M$13.65M$172.49M
Gross margin86.8%88.7%87.5%87.1%86.1%90.3%88.6%88.8%87.7%89.4%
Operating margin11.3%28.5%17.9%9.7%15.1%29.2%22.4%15.2%12.7%29.9%
FCF margin50.0%21.1%14.5%34.7%19.4%45.5%28.0%35.7%4.7%47.3%
SBC / revenue10.2%7.8%10.7%10.1%9.7%8.3%10.1%9.7%10.2%7.9%
Current ratio3.19x2.98x3.17x3.17x3.44x3.04x2.91x2.86x4.14x3.50x
Revenue YoY growth-3.3%7.1%-2.9%0.7%9.3%1.4%13.1%4.9%-3.2%-3.0%
Net margin9.4%24.0%15.4%16.1%14.6%24.8%19.0%19.2%13.3%26.8%
R&D / revenue21.6%16.1%19.9%22.0%20.9%16.7%18.7%22.5%22.7%17.1%
CapEx / revenue4.9%2.3%1.3%5.3%2.0%1.9%1.9%2.4%2.6%2.4%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate33.3%20.3%25.0%-19.2%16.2%23.3%20.9%1.5%20.9%19.3%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DLB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-Q · Filed 2026-01-29View SEC filing
10-K · Filed 2025-11-18View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

cash flow reconciliationreview2024-09-27

Operating, investing and financing flows differ from the reported change in cash by 4384000, beyond tolerance 2613080.00.

cash flow reconciliationreview2023-09-29

Operating, investing and financing flows differ from the reported change in cash by 3699000, beyond tolerance 1000000.